Company / R&D Expense
ENDRA Life Sciences Inc. R&D Expense History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$5.9M
FY2020
5-year range
$1.9M / $5.9M
FY2017-FY2020
Trend
+25.3%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $2M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2020 with a 3-year CAGR of +45.3%.
Improved from $2M to $6M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +45.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +45.3%, indicating consistent growth.
- In FY2020, r&d expense increased 25.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $5.9M | +25.3% |
| FY2019 | $4.7M | +144.6% |
| FY2018 | $1.9M | +0.0% |
| FY2017 | $1.9M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026